NTE.F - Neos Therapeutics, Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
1.2500
+0.0300 (+2.46%)
As of 8:03AM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close1.2100
Open1.2200
Bid1.1900 x 70000
Ask1.3300 x 70000
Day's Range1.2200 - 1.2200
52 Week Range1.0064 - 3.6900
Volume1,000
Avg. Volume53
Market Cap60.739M
Beta (3Y Monthly)2.13
PE Ratio (TTM)N/A
EPS (TTM)-0.7830
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Associated Press

    Neos Therapeutics: 1Q Earnings Snapshot

    The Grand Prairie, Texas-based company said it had a loss of 15 cents per share. The pharmaceutical company posted revenue of $14.6 million in the period. The company's shares closed at $2.08. A year ago, ...

  • GuruFocus.com

    Neos Therapeutics Inc (NEOS) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies. Warning! GuruFocus has detected 1 Warning Sign with NEOS. For the last quarter Neos Therapeutics Inc reported a revenue of $15.4 million, compared with the revenue of $7.11 million during the same period a year ago.

  • Associated Press

    Neos Therapeutics: 4Q Earnings Snapshot

    On a per-share basis, the Grand Prairie, Texas-based company said it had a loss of 23 cents. The pharmaceutical company posted revenue of $15.4 million in the period. For the year, the company reported ...

  • Benzinga

    The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 13) Abbott Laboratories (NYSE: ABT ) Akari Therapeutics ...

  • Neos Therapeutics (NEOS) Reports Q3 Loss, Lags Revenue Estimates
    Zacks

    Neos Therapeutics (NEOS) Reports Q3 Loss, Lags Revenue Estimates

    Neos Therapeutics (NEOS) delivered earnings and revenue surprises of -7.50% and -15.52%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    Neos Therapeutics: 3Q Earnings Snapshot

    The Grand Prairie, Texas-based company said it had a loss of 43 cents per share. The pharmaceutical company posted revenue of $12.5 million in the period. The company's shares closed at $2.58. A year ago, ...